카이노스메드

  • Company
    • ABOUT
    • Company Profile
    • Vision
    • History
    • Board of Directors
    • Executive Management
    • Scientific Advisory Board
    • Location
  • Business
    • BUSINESS
    • R & D Direction
    • Parkinson's drug
    • Anti-Virus
    • Cancer
    • Joint research
  • PIPELINE
    • PIPELINE
    • Parkinson’s Drug
    • AIDS treatment
    • Targeted cancer drug
    • Joint Research
  • 홈으로
  • 사이트맵
  • 메일
  • 메일
Kainos Medicine is a global drug research and development company focused on the discovery of innovative new drug for cancer and infectious disease. Highly experienced R&D people with successful development record of Tamiflu and Fuzeon are leading drug research and development of Kainos.
HIV drug :KM023, non-nucleoside reversetranscriptase inhibitor (NNRTI) as anti HIV drug, was completed phase 1 successfully and has been promoted global licensing-out.
HIV drug :KM023, non-nucleoside reversetranscriptase inhibitor (NNRTI) as anti HIV drug, was completed phase 1 successfully and has been promoted global licensing-out.
Targeted anticancer drug : Kainos is focusing on targeted anticancer drug development in epigenetics, emerging area for novel target for oncology.

사이트맵

기업정보 인사말 | 회사소개 | 비전 | 연혁 | 기술자문그룹 | 주요경영진 | 오시는길 | 인재채용
사업분야 연구개발방향 | 항바이러스 | 항암제 | 대사성질환 | 공동연구
파이프라인 에이즈치료제 | DNMT 저해제 항암제 | DOT1L 저해제 항암제 | EZH2 저해제 항암제 | A3AR 길항제 항암제 | 당뇨비만치료제 | 공동연구
홍보·투자정보 IR·뉴스 | 산업동향 |공지사항 |기타문의 |
고객센터 공지사항 | Q&A

사이트맵

About Kainos Medicine About Kainos Medicine | Vision | History | Board of Directors | Executive Management | Scientific Advisory Board | Location
Business R&D overview | Antiviral drug | Anticancer drug | Joint Research
Pipeline Parkinson’s Drug | HIV drug(KM023) | Targeted anticancer drug | Diabetes/Obesity(KM001) | Research Collaboration